Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

Gene editing is already being used to treat a handful of rare genetic diseases; however, most therapies involve breaking or ...

MaxCyte's technology will support TG Therapeutics' efforts to develop a CD19 CAR T cell therapy program for autoimmune diseases.

Researchers developed an epigenetic editing approach to silence the PCSK9 gene, achieving long-term cholesterol reduction ...

Gene therapies to treat rheumatoid arthritis have evolved slowly, but one is ready to move into human trials and an ...

The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) and rare paediatric disease designation ...

CRISPR booked revenue of just under $36 million. On the bottom line, CRISPR flipped to a generally accepted accounting ...

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Intellia Therapeutics Inc. overhyped its lung-disease therapy study despite inefficiencies and costliness of such viral-editing treatments, sending share prices down 15%, a proposed class action says.

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...

Attorneys general from 22 states filed a lawsuit Monday against the Trump administration for slashing funding for medical and ...